Rineterkib

• UNSPSC Description:

  Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF[1][2].

• Target Antigen:

  ERK; Raf

• Type:

  Dye Reagents

• Related Pathways:

  MAPK/ERK Pathway;Stem Cell/Wnt

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ERK-IN-1.html

• Purity:

  99.83

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](C1=CC(F)=CC(Br)=C1)CNC)C2=CC=C(C3=NC([C@@H]4C[C@H](F)[C@@H](O)CC4)=CN=C3N)C=C2F

• Molecular Weight:

  578.42

• References & Citations:

  [1]CAPONIGRO, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO2018051306A1.|[2]Song Y, et al. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes & Diseases, 2022.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 2

• CAS Number:

  1715025-32-3